Drugs.com - New Drug Approvals

Teva and Alvotech Announce FDA Approval of Interchangeability for Selarsdi (ustekinumab-aekn) with Stelara (ustekinumab)

PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced that the U.S. Food...

May 6, 2025 - 07:00
 0
Teva and Alvotech Announce FDA Approval of Interchangeability for Selarsdi (ustekinumab-aekn) with Stelara (ustekinumab)
PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced that the U.S. Food...
Read More

Tags:

Previous Article

Makeup brush users call for more convenient cleaning solutions, survey finds

Next Article

Knorr-Bremse equips Rome metro trains

Related Posts

Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease

Uplizna (inebilizumab-cdon) is Now the First and Only F...

Apr 26, 2025  0

FDA Approves Conexxence (denosumab-bnht), a Biosimilar to Prolia

FDA Approves Conexxence (denosumab-bnht), a Biosimilar ...

Apr 26, 2025  0

FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to Prolia

FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to...

Apr 26, 2025  0